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Summary 
Recombinant major histocompatibility complex (MHC) class II molecules were expressed with 
extracdlular polypeptide domains reorganized to form heavy (H) and light (L) chains (oq-/31- 
/32 and (x2) analogous to class I. Accurate protein folding and dimerization is demonstrated by 
the ability of this 3 + 1-DR1 construct to bind class II-restricted peptides and stimulate CD4 + 
T  ceils. Cell surface expression of a functional class II molecule consisting of H  and L chains 
supports the validity of current class II models and affirms the evolutionary relatedness of class 
I/II. MHC functions that differ between class I/II may be influenced by domain configuration, 
and the use of domain-shifted constructs will allow examination of this possibility. 
T 
he class I and II molecules encoded in the MHC func- 
tion to bind short peptide fragments and display them 
at the call surface where they can be recognized by CD8 § 
and CD4 + T  cells, respectively. Important differences exist 
in the intracdlular trafficking of these molecules and their 
prindpal sites of peptide acquisition (1).  Class  I molecules 
bind endogenously synthesized peptides of 8-10 amino acids 
in length within the endoplasmic reticulum (2). Conversely, 
class II molecules preferenthlly  bind exogenous peptides, which 
are longer and more variable in length (13-20 residues), in 
an endosomal compartment (3). The ability of class II mole- 
cules to bind longer peptides has suggested  the possibility 
that their peptide binding groove, in contrast to class I, has 
at least one "open" end that accommodates heterogeneous 
peptides by allowing residues to extend away from the class 
II molecule (3). 
Both class I and II MHC molecules are heterodimeric gly- 
coproteins containing four extracdlular domains. Each con- 
tains two membrane proximal domains that bear sequence 
homology to the Ig superfamily, and two membrane distal 
domains that together form the peptide binding and T ceil 
recognition sites. These molecules differ, however, in the dis- 
tribution  of protein domains among the two polypeptide 
chains. Chss I mol~ules consist of a three domain, membrane- 
associated H  chain (c~l-ot2-ot3) and a single domain L chain 
which is not membrane assodated (13z-microglobulin).  In 
contrast, class II molecules consist ofc~ and/3 chains of similar 
size, each containing two protein domains. Class II structure 
has been modeled (4) on the crystallographic structure of class 
I (5, 6), and preliminary reports suggest that the overall con- 
formations of these molecules are indeed similar (7). How- 
ever, it is unknown what structural or functional differences 
result when the peptide binding site is generated by an inter- 
molecular dimer (as in class II) rather than an intramolecular 
dimer (as in class I). 
Using recombinant techniques, we tested the ability of class 
II molecules to assemble in a configuration with polypeptide 
domains reorganized into H and L chains analogous to class 
I. This "3 + 1-DILl" molecule is expressed on the ceil mem- 
brane in a conformation recognized by dass II-specific mAbs. 
Importantly, this construct also functions in antigen presen- 
tation upon pulsing with synthetic peptide antigen. Cell sur- 
face expression of a functional 3 + 1-DR1 molecule provides 
experimental support for the class II binding site model, and 
allows examination of functional properties of dass II mole- 
cules which may be conferred by domain configuration inde- 
pendent of linear amino acid sequence. 
Materials and Methods 
cDNA Clones.  Full-length HLA-DR ce and/3 chain cDNA 
clones in the pCD expression vector were used in these studies. 
The DR.A cDNA, encoding the DK ce chain, was isolated as de- 
scribed (8). The DR.BI*0101 cDNA, encoding the DK[/31"0101] 
(formerly DK1/31) chain (9), was obtained from the American Type 
Culture Collection ([ATCC] Rockv01e, MD). 
Splicing of  cDNA Encoding ot and/3 Chains.  The PCtL method 
of splicing by overlap extension (10) was used to generate cDNAs 
encoding HLA-DR1 chains analogous to H and L chains of class 
I molecules, cDNA encoding the c~1 domain was ligated to the 
/3 chain cDNA, positioned between leader sequence and/3t do- 
main cDNA, yidding a cDNA encoding an oh-/31-/32 chain (see 
Fig. 2). Within the c~1-/31-/32  chain, amino acid 84 of the c~1 do- 
main  is  attached  directly  to  amino  acid 1 of the /31 domain, 
without insertion of"spacer" residues. A transmembrane-associated 
c~z construct was generated by splicing out the c~1 domain, and 
attaching leader sequence cDNA directly to the first amino acid 
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coding a soluble c~2 chain was generated by incorporation  of a stop 
codon at the connecting peptide/transmembrane segment by site- 
directed mutagenesis (11). All cDNA constructs were ligated into 
the original pCD vectors, and the entire DNA insert was sequenced 
to confirm the desired product. 
Abs.  The following HLA class II-specific mAb were used in 
these studies: SG157 (obtained from Sanna Goyert, North Shore 
University Hospital, Manhasset, NY) (12); HU-26 (from Akemi 
Wakisaka, Hokkaido University School of Medicine, Sapporo, Japan) 
(13); LB3.1 (from Joan Gorga, Harvard University,  Cambridge, 
MA) (14); and L243 (ATCC)  (15). 
Transfection.  Cells of the DAP.3 subclone of class II-negative 
murine L cell fibroblasts were transfected using the calcium phos- 
phate coprecipitation method as described (16). Transfections in- 
cluded 1 #g of the pSV2-neo plasmid and 20 #g each of plasmids 
containing DRo~t-fll-fl2 chain and DRo~2 or DKo~2-soluble chain 
cDNA.  Control  transfections,  each  including  1 #g  pSV2-neo 
plasmid, included the following: 20/zg each of plasmids containing 
wild-type DR  c~  and fl chains;  40  #g  of cr 
plasmids;  40 #g of c~2-containing plasmid.  G418-resistant  trans- 
fectant clones with stable surface expression of molecules recog- 
nized by SG157 were isolated by flow cytometric sorting as de- 
scribed  (16). 
T Cell Clones.  HLA-DKl-restricted clone HA-l, specific for 
influenza A hemagglutinin H3 residues 307-319,  was derived by 
in vitro stimulation as described (17), and kindly provided by A. 
Sette (Cytel Corp., San Diego, CA). Clone N3A9 (18), which recog- 
nizes residues 412-425 of the Mycobacterium leprae  65-kD heat shock 
protein, was kindly provided by T. H. M. Ottenhoff (University 
Hospital, Leiden, The Netherlands). 
Peptides.  Peptide HA, representing residues 307-319 of influenza 
A hemagglutinin H3, was purchased from Multiple Peptide Systems 
(San Diego, CA). Peptide HSP-65, containing residues 412-425 of 
the M. leprae 65-kD heat shock protein, was provided by Dr. D. 
C. Anderson (NeoRx Corp., Seattle, WA). Peptides were synthe- 
sized by solid phase methods and HPLC-purified before use. 
T CelIProliferation  Assays.  L cell transfectants expressing human 
MHC molecules  were irradiated  (3,000 tad) and seeded at 2  x 
104.cells/well in 96-well plates. Wells were pulsed overnight with 
peptide at the indicated concentrations, and washed twice with 
PBS before the addition of 5  x  104 T cells/well.  After 48 h cul- 
ture, wells were pulsed for 14-16 h with 1.0 #Ci 3H[TdR],  har- 
vested onto glass filters, and assessed  by liquid scintillation counting. 
Results are expressed as the mean counts per minute of triplicate 
wells. Individual replicates were within 15%  of the mean. 
Metabolic Cell Labeling.  L cell transfectants  were plated in 150 
cm  2 tissue culture flasks at 107 cells/flask and incubated overnight. 
Flasks were washed twice with sterile PBS before the addition of 
leucine-free Eagle's MEM containing 10%  dialysed FCS,  1 mM 
glutamine, penicillin,  streptomycin, and 0.3 pCi/ml 3H-hucine 
(152 Ci/mmol, Amersham Corp., Arlington Heights, IL). Cells 
were incubated for 6 h at 37~  rinsed twice with PBS, and detached 
using a rubber policeman into 5 ml PBS. Cells were centrifuged 
and resuspended  in lysis buffer (150 mM NaC1, 50 mM Tris, pH 
7.4,  1%  NP-40,  0,02%  NAN3, 50  /zg/ml  PMSF,  50  /~g/ml 
leupeptin, 50/~g/ml Pepstatin A) at 3  x  107 cell equivalents/ml. 
Lysates were incubated at 4~  for 30 min, centrifuged at 14,000 
rpm at 4~  for 30 min, and supernatants collected and stored at 
-  20~ 
Immunoprecipitations  and Gel Electrophoresis.  I ml cell lysate was 
precleared by incubation with 300 ~1 Zysorbin G (Zymed Labora- 
tories, Inc., South San Francisco, CA) and 5 Izg MOPC 195 (Cappel 
Laboratories, West Chester, PA) overnight at 40C.  The Zysorbin 
G was pelleted and the supernatant was incubated for 6 h at 4~ 
with  25  #1  protein  G-scpharose  (Pharmacia,  Piscataway,  NJ) 
prearmed by incubation with mAb L243. The protein G-Sepharosc 
was washed twice with TBS, twice with 0.5% Tween X-100 in 
TBS,  then  twice  in  TBS.  After  centrifugation,  the  protein 
G-Sepharose was resuspended in SDS-PAGE reducing sample buffer 
(0.0625 M Tris, 10%  glycerol,  5% r-ME,  2.3% SDS, pH 6.8), 
boiled for 10 min, and vortexed before pelleting. Supernatants were 
analyzed on discontinuous SDS-polyacrylamide gels (5% stacking 
gel,  12.5%  running gel).  Gels were fixed for 30 min in 25% 
isopropanol/10%  acetic acid, soaked for 30 minutes in Amplify 
(Amersham Corp.), dried, and exposed to film for 3-7 d at -70~ 
Results  and  Discussion 
cDNAs encoding fuLl-length DP,  ce and DR.lfl chains were 
spliced to encode chains analogous to the H  and L  chains 
of class  I MHC molecules (Fig.  1). cDNAs were designed 
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Figure  1.  PCR.  splicing of cDNAs encoding DR.loe and fl chains. AB 
and CD fragments were generated in independent PCR reactions, and 
the desired  products were isolated  from agarose gels. In a third PCR reac- 
tion, AB and CD fragments containing overlapping segments were an- 
nealed and extended  to form AD fragments  which incorporate  unique re- 
sttiction enzyme  sites. (A) Formation  of the or2 construct. Splice site primer 
sequences: (B) GGAGGTACAGCCCATGATTCCTGAGCGCTCAT,  and 
(c) CAGGAATCATGGGCTGTACCTCCAGAGGTAAC.  (B) Formation 
of the cxl-flt-fl2  construct. Splice site primer sequences: (B) CGGGTG- 
TCCCCATTGGTGATCGGAGTATAGTT,  and (c) ATCACCAATGGG- 
GACACCCGACCACG. 
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Figure  2.  Schematic representation  of domain configurations  in class 
I molecules,  class II molecules,  and  the 3+1-DR1 construct. 
to encode covalent attachment of the oq domain COOH- 
terminus to the BI domain NH2-terminus,  based upon do- 
main homologies with dass I molecules (patterns of  conserved 
sequence and disulfide bonds) (4). This 3 + 1-DR1 molecule, 
shown diagrammatically in Fig. 2, consists of a three domain 
c~1-~r~2 chain  and  single  domain,  membrane-bound cr 
chain. The membrane distal, NH2-terminal  domains form- 
ing the sites for interaction with peptide and TCR are thus 
contributed by the same polypeptide chain, analogous to dass 
I. In addition, the 3 + 1-DR1 molecule no longer has the cova- 
lent association between oh and o~2 domains characteristic of 
class II molecules. 
After cloning of cDNAs into the pCD expression vector, 
cotransfection of class II-negative murine L cells, and G418 
S  G 157  L243 
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Figure  3.  mAbrecognitionofconventionalDRland3 +  1-DKlmol- 
ecules. Log fluorescence of 5,000 cells is shown for mAbs SG157, L243, 
LB3.1,  and HU26. 
selection, surface expression of molecules recognized by the 
human class II-specific mAb SG157 was detected. Analysis 
of uncloned transfectants receiving o~2 and o~v~1-~2 chains 
demonstrated expression of the 3 + 1-DR1 molecule, whereas, 
transfection of vectors encoding either c~z or cr  chains 
alone did not result in cell surface expression of molecules 
detected by SG157 (data not shown). Also, there was no de- 
tectable cell surface expression of a 3 + 1-DR1 molecule  using 
cDNAs encoding the c~t-/~v,62  chain and a soluble o~2 chain 
construct (data not shown). These results may reflect a re- 
quirement for interactions between transmembrane segments 
of c~ and/3 chains in formation of the class II dimer as re- 
cently described (19). 
L cell clones with stable expression of the SG157 epitope 
were isolated by a single round of flow cytometric sorting 
and tested for recognition by additional mAbs recognizing 
HLA-DR1 (Fig. 3). mAbs L243 and LB3.1 each recognized 
3 + 1-DR1 transfectant  clones comparably to conventional  DILl 
transfectants  that were selected for similar levels of SG157 
expression. However, the epitope recognized  by mAb HU26 
was disrupted in the 3 + 1-DR1 transfectant relative to con- 
ventional DPd-expressing control transfectants. This HLA- 
DR epitope has previously been mapped to/3 chain position 
4 (20), and thus may be disrupted in the 3 + 1-DR1 molecule 
by the covalent attachment of the oL chain to the/3 chain 
NH2 terminus (Fig. 4). However, the overall conformation 
of the 3 + 1-DR1 construct appears to be comparable to con- 
ventional DR1, as demonstrated with mAbs SG157, LB3.1, 
and L243. 
Although the 3 + 1-DR1 H and L chains fold into a struc- 
ture that reconstitutes certain mAb recognition sites, the ability 
of this heterodimer to bind peptide and serve  as a functional 
TCR ligand is a more meaningful test of  conformation. There- 
fore, 3 + 1-DRl-expressing L cell clones were used as APC 
in proliferation assays with antigen-specific, DRl-restricted 
T cell clones. Clones HA-1 and N3A9, specific for peptides 
,% 
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Figure  4.  Predicted  structure of the class II binding region for pep- 
tide/TCg as proposed by Brown et al. (4). The covalent attachment be- 
tween DRoh and fit domains in the 3+1-DK1 construct is shown. The 
location of amino acid residue 4 within the DR 81 domain is indicated. 
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protein, proliferated comparably to peptide-pulsed transfec- 
tants expressing either conventional or 3 + 1-DR1 molecules 
(Fig. 5). Therefore, the class I-like domain configuration did 
not impair the ability of the 3 + 1-DR1 molecule to bind pep- 
tide in a conformation allowing T  cell stimulation. 
Class I molecules bind and present antigenic peptides that 
are shorter and more homogeneous in length compared to 
class II. Peptide truncation analog experiments as well as pep- 
tide elution studies with class I molecules indicate a strong 
preference for 8-10 residue peptides (21, 22). Within the class 
I molecule, pockets of conserved MHC residues at each end 
of the binding groove interact closely  with COOH-  and 
NH2-terminal peptide residues to confer this length prefer- 
ence. Our results demonstrate that 13 and 14 residue pep- 
tides can bind to, and be presented by, the 3 + 1-DR1 con- 
struct.  Thus,  the  covalent  linkage  between  oq  and  ~1 
domains does not disrupt the ability to bind peptides of this 
length, and the "open-endedness" of the class II binding site 
does not appear to depend upon the lack of covalent attach- 
ment between NHTterminal domains. 
Metabolically labeled 3 + 1-DR1 molecules were immuno- 
precipitated and analyzed by SDS-PAGE. The results confirmed 
the expected molecular weights of the o~2 (21 kD) and o~v 
~1-/32 (48 kD) chains  (Fig.  6),  and excludes the possibility 
that L cell clones expressing murine class II molecules were 
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selected. The ol2 chain, in contrast to 32-microglobulin,  con- 
tains connecting peptide, transmembrane, and cytoplasmic 
segments, resulting in a correspondingly higher molecular 
weight. 
Several pieces of evidence support the notion that the ter- 
tiary structures of class I and II molecules are highly homol- 
ogous, including their overall domain composition, the pres- 
ence of a single peptide binding site, patterns of conserved 
amino acids (4),  the ability of certain T  cells to recognize 
either class of MHC molecule (23), and the results of a detailed 
mutational analysis of the murine class II o~ chain (24).  In- 
deed, preliminary reports of the HLA-DR1 structure sug- 
gest the overall validity of this model (7). However, differ- 
ences in domain configuration could translate into important 
differences in quaternary protein structure, flexibility, or func- 
tion. The present data supports the concept that class II as- 
sumes a conformation similar to class I, by demonstrating 
that HLA-DR1 conformation  is not dramatically altered upon 
reorganization of its linear amino acid sequence into H  and 
L chains analogous to class I. 
The different domain configurations of class I and II MHC 
molecules may have evolved because they provide distinct func- 
tional properties related to antigen presentation. Certain MHC 
functions may be permitted, or quantitatively altered, by do- 
main configuration, including peptide selection,  kinetics of 
peptide binding and release, chaperone protein interactions, 
recycling of surface-expressed  molecules, and "retrograde"  sig- 
naling via the MHC molecule to the APC. The expression 
of MHC molecules with identical linear sequence but differing 
domain configurations allows direct testing of the functional 
correlates of domain organization, independent of linear amino 
acid sequence. 
Figure  5.  Proliferation of DILl-restricted T cell clones in response to 
synthetic peptide presented by L cell transfectants.  (A) Clone HA-1 re- 
sponse to pcptide I-IA307.319;  (B) Clone N3A9 response  to peptide HSP- 
654124z5. Incorporation of 3H[TdR], in cpm, at the peptide concentrations 
indicated, was measured  during the last 14 h  of a 60-h incubation. 
Figure  6.  SDS-PAGE analysis of mAb L243 immunoprecipitates using 
transfectants  expressing  conventional DR1  and 3  +  1-DR1 molecules. 
(Lane I) Neo transfcetant  (no class 11 expression);  (lane 2) conventional 
DR1  transfectant;  (lane  3)  3+1-DR1  transfectant.  (MW  standards) 
14C-labeled control proteins. 
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